Sonazoid-enhanced Ultrasound in the Diagnosis and Treatment of Hepatic Tumors
Sonazoid-enhanced Ultrasound in the Diagnosis and Treatment of Hepatic Tumors
复制标题
DOI：
10.1016/s0929-6441(08)60014-4
复制
发表时间：
2008-01-01
影响因子：
1.1
通讯作者：
Maekawa, Kiyoshi
中科院分区：
文献类型：
--
作者：
Kudo, Masatoshi;Hatanaka, Kinuyo;Maekawa, Kiyoshi
Sonazoid是第二代造影剂，于2007年在日本获准独家使用。该造影剂具有两个极其有利的特点：（1）实时血管成像能力，以及（2）血管后相中极其稳定的Kupffer相，持续10-60分钟，允许多次扫描。凭借这些有利的特征，使用 Sonazoid 增强超声 (US) 与 Levovistenhanced US 或多排计算机断层扫描 (MDCT) 进行肝脏肿瘤的鉴别诊断进行了比较。此外，一种新技术“缺陷再灌注成像”使得描述和诊断结节成为可能，这些结节无法通过B型超声识别，但可以通过MDCT检测到。因此，Sonazoid增强超声是肝肿瘤诊断和治疗的突破性技术。
Sonazoid, a second-generation contrast agent, was approved for exclusive use in Japan in 2007. This agent has two extremely favorable features: (1) real-time vascular imaging ability, and (2) an extremely stable Kupffer phase in the postvascular phase for 10-60 minutes allowing multiple scanning. With these favorable features, differential diagnosis of hepatic tumors using Sonazoid-enhanced ultrasound (US) has been compared with Levovistenhanced US or multidetector computed tomography (MDCT). Furthermore, a new technique, "defect reperfusion imaging" has made it possible to depict and diagnose nodules, which are not identified by B-mode US but are detected by MDCT. Thus, Sonazoid-enhanced US is a breakthrough technology in the diagnosis and treatment of hepatic tumors.